Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03618550 · ClinicalTrials.gov registry record · Phase 2

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

A Phase 2 study of Hodgkin Lymphoma and Relapsed or Refractory Hodgkin Lymphoma, sponsored by Memorial Sloan Kettering Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
257
Enrollment target
8
Study locations

NCT03618550 is a Phase 2 study of Hodgkin Lymphoma and Relapsed or Refractory Hodgkin Lymphoma that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 257 participants, above the 162-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (59% higher). The trial reports 8 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03618550, a Phase 2 study of Hodgkin Lymphoma and Relapsed or Refractory Hodgkin Lymphoma, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
257 participants
Enrollment target
8
Study locations

Study Summary

The purpose of this study is to test any good and bad effects of the study drug, pembrolizumab, in combination with GVD in the treatment of Hodgkin lymphoma.

Conditions Studied

Hodgkin Lymphoma Relapsed or Refractory Hodgkin Lymphoma

Interventions

  • DRUG pembrolizumab
  • DRUG gemcitabine
  • DRUG vinorelbine
  • DRUG liposomal doxorubicin
  • PROCEDURE Stem cell mobilization and collection

Study Locations (8)

New York

  • Memorial Sloan Kettering Cancer Center @ Commack - Commack
  • Memorial Sloan Kettering Westchester - Harrison
  • Memorial Sloan Kettering Cancer Center - New York
  • Memorial Sloan Kettering Nassau - Uniondale

New Jersey

  • Memorial Sloan Kettering Basking Ridge - Basking Ridge
  • Memorial Sloan Kettering Monmouth - Middletown
  • Memorial Sloan Kettering Bergen - Montvale

Florida

  • University of Miami - Miami

Trial Details

FieldValue
Enrollment Target 257 participants
Start Date 2018-08-01
Est. Completion 2026-08
Phase Phase 2

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03618550

The ClinicalTrials.gov registry entry for NCT03618550 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 257 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 162-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (59% higher). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Hodgkin Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which pembrolizumab is the first listed.

NCT03618550 reports 8 study locations spanning 3 distinct geographic areas - top geographies include New York, New Jersey, Florida.

Frequently Asked Questions

What is clinical trial NCT03618550 about?

NCT03618550 is a clinical study titled "Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma". The purpose of this study is to test any good and bad effects of the study drug, pembrolizumab, in combination with GVD in the treatment of Hodgkin lymphoma.

What is the current status of trial NCT03618550?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 257 participants. The study started on 2018-08-01. Estimated completion is 2026-08.

What conditions does trial NCT03618550 study?

This clinical trial studies the following conditions: Hodgkin Lymphoma, Relapsed or Refractory Hodgkin Lymphoma.

What interventions are being tested in trial NCT03618550?

The interventions under investigation include: pembrolizumab (DRUG), gemcitabine (DRUG), vinorelbine (DRUG), liposomal doxorubicin (DRUG), Stem cell mobilization and collection (PROCEDURE).

Who is sponsoring clinical trial NCT03618550?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03618550 being conducted?

This trial has 8 study locations across Florida, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hodgkin Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hodgkin Lymphoma

All registered trials for this condition

Relapsed or Refractory Hodgkin Lymphoma

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.